Literature DB >> 12187265

No association of serum gonadal or pituitary hormones with prognostic parameters in stages T1 to T3 PN0M0 prostate cancer.

Philip Fodstad1, Trine Bjøro, Goran Torlakovic, Sophie D Fossa.   

Abstract

PURPOSE: Recent reports suggest a possible association of the clinical aggressiveness of prostate cancer with low serum testosterone, and high serum levels of lutenizing hormone (LH) and/or follicle-stimulating hormone (FSH). This hypothesis was tested in the current study.
MATERIALS AND METHODS: Serum levels of testosterone, LH, FSH, estradiol and sex hormone-binding globulin were determined as well as the calculated ratio of testosterone-to-sex hormonebinding globulin in 370 patients with newly diagnosed, stages T1 to T3 pN0M0 prostate cancer. The results were related to T category, Gleason score and serum prostate specific antigen (PSA).
RESULTS: No statistically significant association was found for the serum levels of testosterone, LH, FSH, estradiol, sex hormone-binding globulin or the testosterone-to-sex hormone-binding globulin ratio with T category, Gleason score or PSA. In contrast to expectations, serum testosterone values within the lowest quartile were not associated with elevated LH. Of the 370 patients 17 (5%) had serum testosterone below the normal range (8 nmol./l. or less) and only 3 of these 17 showed elevated LH levels.
CONCLUSIONS: Serum levels reflecting the pituitary-gonadal axis at diagnosis are not associated with clinically used measures of tumor aggressiveness (T category, Gleason score or PSA) in patients with newly diagnosed T1 to T3 pN0M0 prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12187265     DOI: 10.1097/01.ju.0000025040.08466.9c

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

1.  Preoperative Plasma Levels of Total Testosterone Associated with High Grade Pathology-Detected Prostate Cancer: Preliminary Results of a Prospective Study in a Contemporary Cohort of Patients.

Authors:  Antonio B Porcaro; Nicolò De Luyk; Paolo Corsi; Marco Sebben; Alessandro Tafuri; Giovanni Cacciamani; Davide De Marchi; Irene Tamanini; Davide Inverardi; Matteo Brunelli; Maria A Cerruto; Gian L Salvagno; Gian C Guidi; Walter Artibani
Journal:  Curr Urol       Date:  2017-05-30

2.  Simultaneous Measurements of Follicle Stimulating Hormone and Total Testosterone and Associations in Clinically Localized Prostate Cancer.

Authors:  Antonio B Porcaro; Salvatore Siracusano; Nicolò de Luyk; Paolo Corsi; Marco Sebben; Alessandro Tafuri; Tania Processali; Davide Inverardi; Giovanni Cacciamani; Daniele Mattevi; Maria A Cerruto; Matteo Brunelli; Claudio Ghimenton; Carmelo Monaco; Walter Artibani
Journal:  Curr Urol       Date:  2017-10-22

3.  Body mass index in early and middle-late adulthood and risk of localised, advanced and fatal prostate cancer: a population-based prospective study.

Authors:  A Discacciati; N Orsini; S-O Andersson; O Andrén; J-E Johansson; A Wolk
Journal:  Br J Cancer       Date:  2011-08-16       Impact factor: 7.640

4.  Prostate cancer volume associates with preoperative plasma levels of testosterone that independently predicts high grade tumours which show low densities (quotient testosterone/tumour volume).

Authors:  Antonio B Porcaro; Aldo Petrozziello; Matteo Brunelli; Filippo Migliorini; Giovanni Cacciamani; Davide De Marchi; Nicolo' de Luyk; Irene Tamanini; Beatrice Caruso; Maria A Cerruto; Claudio Ghimenton; Walter Artibani
Journal:  Asian J Urol       Date:  2015-11-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.